Tables S1-S10 from MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition

作者：Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, Jeeyun Lee, Stephan Grabbe, Piotr Rutkowski, Jacek Mackiewicz, Katy K. Tsai, Paolo A. Ascierto, Mario Mandalà, Fabrizio Carnevale‐Schianca, Sebastian Haferkamp, Victoria Atkinson, Jessica C. Hassel, Shahneen Sandhu, William H. Sharfman, Emma Dean, Urwah Noor, Sonia Iyer, Roy Rabbie, Antoni Ribas · 年份：2026 · DOI：10.1158/1078-0432.33014429 · 研究领域：Medicine、Oncology、Internal medicine

<p>Supplementary tables including inclusion/exclusion criteria, representativeness of study participants, objective response rate by stratification factors and melanoma subtype, AEs, SAEs, AESIs, Baseline patient and disease characteristics in PD-L1 biomarker evaluable population, CD8/Ki67 evaluable population, baseline circulating immune cell population and GDF-15 evaluable population.</p>